SCH56592 treatment of murine invasive aspergillosis

被引：41

作者：

Graybill, JR

Bocanegra, R

Najvar, LK

Luther, MF

Loebenberg, D

机构：

[1] Audie L Murphy Mem Vet Hosp, Div Infect Dis 111F, San Antonio, TX 78284 USA

[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA

[3] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 1998年 / 42卷 / 04期

关键词：

D O I：

10.1093/jac/42.4.539

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Mice were immunosuppressed using corticosteroids and infected with conidia of Aspergillus fumigatus. Beginning 1 day after infection, mice were treated orally either with Noble agar or with SCH56592 suspended in Noble agar, or intraperitoneally with amphotericin B. SCH56592 prolonged survival and reduced lung tissue counts of A. fumigatus, while amphotericin B had marginal benefit. SCH56592 merits further development for treatment of aspergillosis.

引用

页码：539 / 542

页数：4

共 25 条

[1] TREATMENT OF MURINE CRYPTOCOCCAL MENINGITIS WITH AN SCH-39304-AMPHOTERICIN-B COMBINATION [J].

ALBERT, MM ;

GRAYBILL, JR ;

RINALDI, MG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (09) :1721-1725

[2] THE EMERGING ROLE OF FUSARIUM INFECTIONS IN PATIENTS WITH CANCER [J].

ANAISSIE, E ;

KANTARJIAN, H ;

RO, J ;

HOPFER, R ;

ROLSTON, K ;

FAINSTEIN, V ;

BODEY, G .

MEDICINE, 1988, 67 (02) :77-83

[3]

ANAISSIE EJ, 1992, J INFECT DIS, V165, P1155, DOI 10.1093/infdis/165.6.1155

[4] EMERGING FUNGAL PATHOGENS [J].

ANAISSIE, EJ ;

BODEY, GP ;

RINALDI, MG .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (04) :323-330

[5]

[Anonymous], 1992, M27P NCCLS

[6] THERAPY OF MURINE ASPERGILLOSIS WITH AMPHOTERICIN-B IN COMBINATION WITH RIFAMPIN OR 5-FLUOROCYTOSINE [J].

ARROYO, J ;

MEDOFF, G ;

KOBAYASHI, GS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1977, 11 (01) :21-25

[7]

COLEMAN JM, 1995, NEUROSURGERY, V36, P858, DOI 10.1097/00006123-199504000-00032

[8]

DEBOCK R, 1994, BONE MARROW TRANSPL, V14, pS1

[9] NIAID MYCOSES STUDY-GROUP MULTICENTER TRIAL OF ORAL ITRACONAZOLE THERAPY FOR INVASIVE ASPERGILLOSIS [J].

DENNING, DW ;

LEE, JY ;

HOSTETLER, JS ;

PAPPAS, P ;

KAUFFMAN, CA ;

DEWSNUP, DH ;

GALGIANI, JN ;

GRAYBILL, JR ;

SUGAR, AM ;

CATANZARO, A ;

GALLIS, H ;

PERFECT, JR ;

DOCKERY, B ;

DISMUKES, WE ;

STEVENS, DA .

AMERICAN JOURNAL OF MEDICINE, 1994, 97 (02) :135-144

[10] OROPHARYNGEAL CANDIDIASIS IN IMMUNOCOMPROMISED CHILDREN - A RANDOMIZED, MULTICENTER STUDY OF ORALLY-ADMINISTERED FLUCONAZOLE SUSPENSION VERSUS NYSTATIN [J].

FLYNN, PM ;

CUNNINGHAM, CK ;

KERKERING, T ;

SANJORGE, AR ;

PETERS, VB ;

PITEL, PA ;

HARRIS, J ;

GILBERT, G ;

CASTAGNARO, L ;

ROBINSON, P ;

WALD, E ;

WOLFE, LC ;

KOVACS, A ;

YU, L ;

RUBENSTEIN, A ;

KRAMER, B ;

PARYANI, S ;

BUNIN, N ;

COX, FE ;

SANJOAQUIN, V ;

GREFFE, B ;

CULLEN, J ;

YOGEV, R ;

NOEL, G ;

HOLDSWORTH, M ;

YAMAUCHI, T ;

PETRU, A ;

LUKENS, J ;

PARKS, B ;

POWELL, K ;

SCHWARTZ, C ;

DAJANI, A ;

DAHL, GV ;

BRYSON, Y ;

MAURER, H ;

GOOCH, M ;

SULLIVAN, B ;

VANDYKE, R ;

WEINER, LB ;

SCOTT, G ;

RODRIGUEZ, Z ;

LOWN, K ;

WARFORD, R ;

PELTON, S ;

BOROWSKI, G ;

NORTON, B ;

MALLOY, J .

JOURNAL OF PEDIATRICS, 1995, 127 (02) :322-328

← 1 2 3 →